dextromethorphan hydrobromide | 125-68-8

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 吗啡烷
• 英文名称: dextromethorphan hydrobromide
• 英文别名: dextromethorphan；hydron;(1R,9R,10R)-4-methoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-triene;bromide
• CAS: 125-68-8
• 化学式: BrH*C₁₈H₂₅NO
• 分子量: 352.315
• InChiKey: MISZALMBODQYFT-FLCXFYETSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.96
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  12.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  dextromethorphan hydrobromide 在 氢溴酸 作用下， 以100%的产率得到左啡诺
  参考文献：
  名称：

  Anticonvulsant effects of new morphinan derivatives

  摘要：

  We synthesized a series of compounds that are modified in positions 3 and 17 of the morphinan ring system, with the intention of developing ideal anticonvulsant agents. We examined the effects of these compounds on kainic acid (KA)-induced seizures, and on locomotor patterns in rats. We found that compounds 5. 6. and 8 exhibit novel anticonvulsant effects, with negligible psychotropic effects. (C) 2001 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(01)00262-1

文献信息

• Non-Cryogenic, Ammonia-Free Reduction of Aryl Compounds
  申请人：University of Pittsburgh - Of the Commonwealth System of Higher Education

  公开号：US20220089508A1

  公开（公告）日：2022-03-24

  A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from −20° C. to 30° C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

  在化合物中减少芳香环或环状烯丙基醚的方法包括准备反应混合物，其中包括含有芳香基团或环状烯丙基醚基团的化合物，一种碱金属，以及乙二胺、二乙二胺、三乙二胺或其组合物之一，在醚溶剂中；并将反应混合物在-20°C至30°C的温度下反应一段足够时间，以将芳香基团中的双键还原为单键，或减少环状烯丙基醚基团。
• METHODS FOR PREPARING LEVORPHANOL AND RELATED COMPOUNDS, AND COMPOSITIONS THEREOF
  申请人：AMPAC Fine Chemicals LLC

  公开号：US20200109119A1

  公开（公告）日：2020-04-09

  A method for producing substantially pure levorphanol and related compounds, when compared to the conventional process, is provided. In particular, a method for producing substantially pure levorphanol tartrate dihydrate is described. Also described are compositions comprising levorphanol and related compounds, particularly compositions comprising levorphanol tartrate dihydrate, levomethorphan, and norlevorphanol in which the levomethorphan and norlevorphanol are present in the composition in reduced levels.

  提供了一种与传统工艺相比，用于生产几乎纯的左旋吗啡和相关化合物的方法。具体描述了一种生产几乎纯的左旋吗啡酒石酸二水合物的方法。还描述了包含左旋吗啡和相关化合物的组合物，特别是包含左旋吗啡酒石酸二水合物、左美啡和去氧左旋吗啡的组合物，其中左美啡和去氧左旋吗啡在组合物中的含量降低。
• Process for the Production of Levorphanol and Related Compounds
  申请人：Haar Joseph P.

  公开号：US20080146805A1

  公开（公告）日：2008-06-19

  A process for the production of morphinans with higher purity and yield, when compared to the conventional process, is described. Specifically, the process may be used to prepare levorphanol, levorphanol tartrate, and levorphanol tartrate dihydrate in high yields and substantially free from several process impurities.

  本发明描述了一种生产吗啡类化合物的工艺，与传统工艺相比，可获得更高纯度和产量。具体而言，该工艺可用于制备左旋麻黄碱、左旋麻黄碱酒石酸盐和左旋麻黄碱酒石酸盐二水合物，其收率高，基本上不含多种工艺杂质。
• Preparations containing silicon dioxide to improve the taste thereof
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1166801A1

  公开（公告）日：2002-01-02

  A pharmaceutical preparation comprising a bitter tasting mixture of a decongestant such as pseudoephedrine and an antihistamine such as diphenhydramine and/or chlorpheniramine maleate is made with no bitter, metallic taste or unpleasant mouthfeel by adsorbing the active drug mixture using a wet granulation process onto a silicon dioxide carrier which comprises from about 50 to about 85 % of total weight of the adsorbate composition. A truly multi-symptom relief formula is prepared through the optional addition of an antitussive such as dextromethorphan hydrobromide and/or an analgesic such as meclofenamic acid, aspirin or ibuprofen. Additional excipients such as flavors, sweeteners, lubricants and bulk fillers are added for better taste, improved mouthfeel and as an aid to the tabletting process. Preferred preparations ar chewable tablets.

  将活性药物混合物用湿法造粒工艺吸附在二氧化硅载体上，可制成一种含有减充血剂（如伪麻黄碱）和抗组胺剂（如苯海拉明和/或马来酸氯苯那敏）的苦味混合物的药物制剂，该载体占吸附剂组合物总重量的约 50%至约 85%，因此不会产生苦味、金属味或难闻的口感。可选择添加右美沙芬氢溴酸盐等止咳药和/或甲氯芬那酸、阿司匹林或布洛芬等镇痛药，制备出真正的多种症状缓解配方。添加其他辅料，如香精、甜味剂、润滑剂和散装填料，可改善口感和口感，并有助于压片过程。首选制剂为咀嚼片。
• Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
  申请人：The Scripps Research Institute

  公开号：US10660899B2

  公开（公告）日：2020-05-26

  The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

  本发明提供了用神经递质受体调节剂诱导少突胶质祖细胞向成熟髓鞘细胞命运分化的方法。本发明还提供了通过施用所述神经递质受体调节剂刺激有需要的受试者增加髓鞘化的方法。本发明还提供了使用神经递质受体调节剂治疗脱髓鞘疾病的方法。